July 17, 2018
Lisa Folberg, MPP Will Be New CAFP EVP-CEO
Lisa Folberg, MPP has been selected as CAFP’s new Executive Vice President-Chief Executive Officer (EVP-CEO), after recommendation by the Academy’s Search Committee and final approval by the Board of Directors at its Saturday, July 14 meeting in Oakland. CAFP undertook a nationwide search to identify a successor to current EVP Susan Hogeland, CAE, who will retire after 27 years with the Academy on September 30.
Ms. Folberg has 18 years of experience in government relations, management, health policy and program development and most recently served for three years as President and CEO of the California Medical Association Foundation (CMAF – now known as Physicians for a Healthy California). She helped build the Network of Ethnic Physician Organizations (NEPO) at CMAF. Previously, Ms. Folberg served as Vice President, Medical and Regulatory Policy and Associate Director, Government Relations for the California Medical Association, and as Senior Fiscal and Policy Analyst for the California Legislative Analyst’s Office. She received her undergraduate degree at San Francisco State University and her Master of Public Policy from Georgetown University.
CAFP wishes to thank the members of the Search Committee, who labored long and hard to identify the right new staff leader for the Academy: Michelle Quiogue, MD, Chair, Raul Ayala, MD, Shannon Connolly, MD, Steve Green, MD, Susan Hogeland, CAE, Walt Mills, MD, Lee Ralph, MD, Shelly Rodrigues, CAE and Lisa Ward, MD, MScPH, MS. Congratulations, Ms. Folberg, and welcome to CAFP.
Board Meeting Short but Packed
The CAFP Board met for just 2.5 hours on Saturday, July 14 in Oakland, but managed to accomplish five hours’ worth of work. The Board welcomed Ms. Lisa Folberg, MPP, CAFP’s future EVP-CEO, who spent the weekend at the Board and engagement planning meetings learning about Academy issues. Positions on a variety of bills pending before the State Legislature were updated and positions were taken on initiatives that have qualified, or are likely to, for the November state ballot. The 2017 Financial Review was approved and updates were given on CAFP’s support of an ACLU lawsuit against the Food and Drug Administration to rescind the REMS (Risk Evaluation and Mitigation Strategy) on mifepristone, as well as anticipated legal fees associated with a subpoena CAFP received for a civil lawsuit by Orange and Santa Clara counties against Purdue Pharma, LP, et al.
The Board acted on a number of resolutions submitted at the All Member Advocacy Meeting (AMAM) or after and adopted a policy for ensuring members have an opportunity to comment on resolutions submitted after the AMAM before they are considered by the Board, and for keeping members informed about actions the Board has taken on all resolutions. The Board approved several resolutions for submission to the AAFP’s Congress of Delegates in October, including “Removing REMS Categorization on Mifepristone,” “Reject ‘Assisted Suicide’ Terminology in Aid-in-Dying,” “Medical Aid in Dying Is an Ethical End-of-Life Choice” and “Two Percent Tax on Gun and Ammunition Sales” to support mental health services. Additionally, CAFP’s 2018 Delegation to the California Medical Association’s House of Delegates was approved: Drs. Ashby Wolfe, Michelle Quiogue, Lisa Ward, Felix Nunez and Thomas Balsbaugh (not confirmed). Thanks to all.
CAFP-Supported Drug Cost Law May Be Paying Off
Governor Brown signed CAFP-supported SB 17 last year, a bill that, among other things, requires pharmaceutical companies to notify the state and health insurers if they plan to increase the price of a drug (with wholesale cost of $40 or higher) more than 16 percent over two years and explain the reasons for the price increase. As a result, a handful of the world’s largest drug manufacturers are canceling or reducing planned price increases. Novartis AG, Gilead Sciences Inc., Roche Holding AG and Novo Nordisk A/S sent notices to California health plans rescinding or reducing previously announced price hikes on at least 10 drugs. The prices of drugs are often obscured by discounts and rebates between insurers, manufacturers, patients and pharmacy benefit managers. Close monitoring will be important to ensure these reductions are not part of maneuvering that will eventually lead to price increases in the future.
Improved Transparency on CAFP Policy Resolutions
Two steps have been taken to ensure members are kept abreast of resolutions submitted to the Board of Directors between All Member Advocacy Meetings (AMAM) or after the deadline for submission of resolutions to the AMAM, have an opportunity to comment on those resolutions and are informed about Board actions taken subsequently on those resolutions:
Questions or comments on this policy are welcome. Please contact CAFP at email@example.com. Thank you. If you have a policy you'd like to submit to CAFP at any time of the year, please use the CAFP Policy Resolution form to do so.
Come to the Summit for ½ the Price of Dinner
Join us in Los Angeles on September 8 for our 10th Family Medicine Summit! Early Bird ends Friday, July 20.
NIDA Launches Science to Medicine (STM) to Help with Opioid Use Disorder
Several studies have demonstrated the efficacy of medication treatment for opioid use disorder (OUD) and long-term outcomes have shown positive improvements, with substantial declines in opioid and other substance use.1
To help you operationalize this science in your practice, NIDAMED interviewed six clinicians in a variety of practice settings for a new series called Science to Medicine (STM). STM briefly summarizes key steps the six clinicians took to successfully integrate medication treatment into their practice setting (e.g., an FQHC, primary care, emergency medicine, pediatrics). STM also offers a brief overview of the latest science across several practice settings. The science, combined with the clinician’s key steps and additional resources, can help you implement medication treatment for OUD into your practice.
UPDATE: Improved Parkinson's Reporting Requirements
Effective July 1, 2018, physicians and licensed practitioners are required to report cases of Parkinson’s disease to the California Department of Public Health (CDPH). All providers required to report must first register with CDPH through its designated gateway. CDPH has revised its California Parkinson’s Disease Registry Implementation Guide to address several concerns voiced from CAFP and others about the original proposal. The guide provides information for reporting Parkinson’s disease data and outlines who is required to report, the timeline for reporting and the manual and electronic methods for transmitting data to the California Parkinson’s Disease Registry. The updates to the guide include limiting the number of reportable ICD-10 codes to only patient encounters for diagnosis or treatment of Parkinson’s Disease or Parkinsonism occurring on or after July 1, 2018. While any encounter type can trigger the requirement to report (e.g., outpatient visits), ancillary encounters are excluded (e.g., lab, imaging, cardio-pulmonary and therapies). The revised Implementation Guide provides a flow chart of reportable Parkinson’s Disease cases to assist providers in determining their reporting obligations. CDPH also extended the reporting compliance date for cases encountered during the first quarter the law is in effect (July 1 to September 30, 2018) from 90 days to 180 days. Beginning October 2, 2018, all cases must be reported within 90 days.
Review 2017 MIPS Scores and Performance Reports NOW
Physicians who participated in the 2017 Merit-based Incentive Payment System (MIPS) have until September 30 to check their performance feedback and final scores and request a review if necessary. Under the Medicare Access and CHIP Reauthorization Act (MACRA), physicians need to use the Quality Payment Program website and choose one of two different payment pathways: Advanced Alternative Payment Models (APMs) or MIPS. Physicians participating in the MIPS pathway can avoid payment penalties and receive bonuses by submitting care quality data.
1. Weiss RD, Potter JS, Griffin ML, Provost SE, Fitzmaurice GD, McDermott KA,…Carroll KM. Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study. Drug Alcohol Depend. 2015;150. doi: 10.1016/j.drugalcdep.2015.02.030↩